Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Corneal Nerve Fiber Length In Hereditary Transthyretin Amyloidosis Polyneuropathy
Neuromuscular and Clinical Neurophysiology (EMG)
P14 - Poster Session 14 (8:00 AM-9:00 AM)
1-001

To describe corneal nerve fiber length (CNFL) in hereditary transthyretin amyloidosis (hATTR) polyneuropathy.

Transthyretin hereditary amyloidosis (hATTR) is a progressive, multi-system disease, that includes degeneration of small and large nerve fibers.  In vivo Corneal Confocal Microscopy (IVCCM) has emerged as an important tool for the evaluation of small nerve fiber structure and has been associated with both large and small-fiber neuropathy in diabetes mellitus. It shows comparable performance for small nerve fibers to Intraepidermal Nerve Fiber Density evaluation, with the advantage of being non-invasive.  CNFL is the most sensitive IVCCM parameter to detect small-fiber neuropathy and can be abnormal before large-fiber neuropathy is demonstrable.

We performed a retrospective cross-sectional study of hATTR patients who had IVCCM and automated CNFL measurements, clinical assessments and nerve conduction studies (NCS) from February to October 2019. CNFL ≤10.7 mm/mm2 is the normal cut-off according to our laboratory normative values.

We included 9 patients, 1/3 female, with a mean age 61.7±8.8 years,  and age of neuropathy onset 56.9±9.0 years. Of these, 8 (88%) had abnormal NCS and all had abnormal CNFL. Mean CNFL was 7.49 ± 1.70 mm/mm2 (range 4.71- 9.90 mm/mm2). Sural nerve sensory potentials were abnormal in 7 patients. There was a trend to a negative association between age (r=-0.56) and age of neuropathy onset (r=-0.59) with CNFL.

In patients with hATTR polyneuropathy, CNFL is able to detect impairment in small nerve fibers and may prove useful in detection of early neuropathy and early response to therapy.  Further studies are needed to assess CNFL in various stages of hATTR neuropathy and the reliability of this measure in monitoring disease progression.

Authors/Disclosures
Monica Alcantara, MD (Toronto General Hospital)
PRESENTER
No disclosure on file
No disclosure on file
Bruce A. Perkins, MPH (Toronto General Hospital) No disclosure on file
Vera Bril, MD (Toronto General Hospital) Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CSL. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alnylam. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Grifols. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Octapharma. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Powell Mansfield. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Akcea. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ionis. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Immunovant. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Momenta (now J&J). Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NovoNordisk. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunovant. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Bril has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Akcea. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for CSL. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. The institution of Dr. Bril has received research support from UCB. The institution of Dr. Bril has received research support from Argenx. The institution of Dr. Bril has received research support from Momenta (now J&J). The institution of Dr. Bril has received research support from Immunovant. The institution of Dr. Bril has received research support from Alexion. The institution of Dr. Bril has received research support from Takeda. The institution of Dr. Bril has received research support from Grifols. The institution of Dr. Bril has received research support from CSL. The institution of Dr. Bril has received research support from Octapharma. The institution of Dr. Bril has received research support from Akcea. The institution of Dr. Bril has received research support from Ionis. The institution of Dr. Bril has received research support from Viela Bio (now Horizon). Dr. Bril has received intellectual property interests from a discovery or technology relating to health care.